YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms
暂无分享,去创建一个
G. Reid | M. Grusch | A. Burgess | K. Schelch | M. Kennerson | T. Johnson | K. Marzec | K. Lai
[1] L. Ovchinnikov,et al. Y-Box Binding Proteins in mRNP Assembly, Translation, and Stability Control , 2020, Biomolecules.
[2] P. Bhatia,et al. Critical Role for Cold Shock Protein YB-1 in Cytokinesis , 2020, bioRxiv.
[3] P. Baas,et al. Immunotherapy in Malignant Pleural Mesothelioma , 2020, Frontiers in Oncology.
[4] Yuwei Zhang,et al. Y‐box protein 1 promotes hypoxia/reoxygenation‐ or ischemia/reperfusion‐induced cardiomyocyte apoptosis via SHP‐1‐dependent STAT3 inactivation , 2020, Journal of cellular physiology.
[5] I. Kulakovskiy,et al. YB-3 substitutes YB-1 in global mRNA binding , 2020, RNA biology.
[6] C. Elizabeth Caldon,et al. Label free, quantitative single-cell fate tracking of time-lapse movies , 2019, MethodsX.
[7] L. Jensen,et al. SnapShot: S-Phase Entry and Exit , 2019, Cell.
[8] G. Reid,et al. Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma , 2019, Front. Cell Dev. Biol..
[9] Hee-Gu Lee,et al. Regulation of Rho GTPases by RhoGDIs in Human Cancers , 2019, Cells.
[10] B. Bay,et al. Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression. , 2019, Cancer letters.
[11] T. Sudo,et al. Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer. , 2019, Oncology reports.
[12] Jinxin Zhu,et al. YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway , 2019, Drug design, development and therapy.
[13] Y. Li,et al. HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer , 2018, Cancer science.
[14] F. Hirsch,et al. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] J. Testa,et al. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas , 2018, Journal of cellular physiology.
[16] Wen-xian Hu,et al. The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth , 2018, Cell Death & Disease.
[17] M. Hentze,et al. The RNA-binding protein YBX1 regulates epidermal progenitors at a posttranscriptional level , 2018, Nature Communications.
[18] C. Pirker,et al. Dysregulated Expression of the MicroRNA miR‐137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] Lungen Lu,et al. Y-box Protein-1 Regulates the Expression of Collagen I in Hepatic Progenitor Cells via PDGFR-β/ERK/p90RSK Signalling , 2017, Stem cells international.
[20] O. Lavrik,et al. At the Interface of Three Nucleic Acids: The Role of RNA-Binding Proteins and Poly(ADP-ribose) in DNA Repair , 2017, Acta naturae.
[21] O. Lavrik,et al. Y-box-binding protein 1 as a non-canonical factor of base excision repair. , 2016, Biochimica et biophysica acta.
[22] Dmitriy Sonkin,et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.
[23] Y. Oda,et al. Nuclear expression of Y‐box binding protein‐1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models , 2016, International journal of cancer.
[24] W. Guo,et al. YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma , 2016, Oncotarget.
[25] A. Ridley,et al. Regulating Rho GTPases and their regulators , 2016, Nature Reviews Molecular Cell Biology.
[26] B. Milleron,et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.
[27] R. Baxter,et al. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage , 2015, Oncotarget.
[28] A. Kawaguchi,et al. Centrosome maturation requires YB-1 to regulate dynamic instability of microtubules for nucleus reassembly , 2015, Scientific Reports.
[29] B. Ghanim,et al. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study , 2015, British Journal of Cancer.
[30] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[31] Hua Yu,et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.
[32] Yan Zhou,et al. Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes , 2014, Molecular Cancer Research.
[33] M. Kitagawa,et al. YB‐1 promotes transcription of cyclin D1 in human non‐small‐cell lung cancers , 2014, Genes to cells : devoted to molecular & cellular mechanisms.
[34] D. Bell,et al. CSF1 Is a Novel p53 Target Gene Whose Protein Product Functions in a Feed-Forward Manner to Suppress Apoptosis and Enhance p53-Mediated Growth Arrest , 2013, PloS one.
[35] M. Lind,et al. PTEN protein expression in malignant pleural mesothelioma , 2013, Tumor Biology.
[36] K. Kuroiwa,et al. YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α , 2013, Cancer Immunology, Immunotherapy.
[37] A. Rosenwald,et al. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival , 2013, Leukemia.
[38] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[39] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[40] A. Shelling,et al. YB-1, the E2F pathway, and regulation of tumor cell growth. , 2012, Journal of the National Cancer Institute.
[41] F. Maldonado,et al. Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[42] P. Hieter,et al. YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction, and HER2 amplification , 2011, Oncogene.
[43] L. Corcos,et al. Cotranscriptional exon skipping in the genotoxic stress response , 2010, Nature Structural &Molecular Biology.
[44] H. Izumi,et al. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. , 2010, European journal of cancer.
[45] K. Shirouzu,et al. YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells. , 2009, Future Oncology.
[46] T. Nielsen,et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy , 2007, Breast Cancer Research.
[47] M. Zvelebil,et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 , 2006, Nature Genetics.
[48] N. Sonenberg,et al. Akt-Mediated YB-1 Phosphorylation Activates Translation of Silent mRNA Species , 2006, Molecular and Cellular Biology.
[49] J. Royds,et al. Y-box factor YB1 controls p53 apoptotic function , 2005, Oncogene.
[50] Hua Yu,et al. Role of Stat3 in Regulating p53 Expression and Function , 2005, Molecular and Cellular Biology.
[51] M. Ladanyi. Implications of P16/CDKN2A deletion in pleural mesotheliomas. , 2005, Lung cancer.
[52] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[53] M. Lebel,et al. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. , 2004, Nucleic acids research.
[54] P. Vogt,et al. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[55] C. Homer,et al. The Y-box-binding Protein, YB1, Is a Potential Negative Regulator of the p53 Tumor Suppressor* , 2003, Journal of Biological Chemistry.
[56] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.
[58] H. Takano,et al. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression , 2000, Oncogene.
[59] H. Gascan,et al. Functional Interaction of STAT3 Transcription Factor with the Cell Cycle Inhibitor p21 WAF1/CIP1/SDI1 * , 2000, The Journal of Biological Chemistry.
[60] A. Grimberg. P53 and IGFBP-3: apoptosis and cancer protection. , 2000, Molecular genetics and metabolism.
[61] H. Takano,et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. , 1999, Cancer research.
[62] C. L. Ventola. Cancer Immunotherapy, Part 3: Challenges and Future Trends. , 2017, P & T : a peer-reviewed journal for formulary management.
[63] J. Cai,et al. HOTAIR: a cancer-related long non-coding RNA. , 2014, Neoplasma.
[64] David Z. Chen,et al. METHOD Open Access , 2014 .
[65] C. Print,et al. YB-1: oncoprotein, prognostic marker and therapeutic target? , 2013, The Biochemical journal.